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Sera from 101 patients with progressive systemic sclero-
derma were analyzed for circulating aminopropeptides of 
type III collagen using a radioimmunoassay which mea-
sures the intact and degraded forms (Fab assa y). About 
41 % of the patients were found to have values above the 
normal range. A good correlation was observed between 
eleva ted levels of aminopropeptides and the degree of in-
volvement of the skin and internal organs in the patients . 
Progressive systemic scleroderma (PSS) is a generalized disorder involvin g m ainly the skin, lungs, kidneys, gas-troint~stinal tract, and hea rt [1-3]. Excess ive deposition of connective tissue components leads to fibrosis and sclerosis of these organs [4]. Similarly to m any o ther 
chronic diseases, PSS is know n to occur in various phases with 
and w ithout acti ve progression [1,5] . Judgem ent of prognosis has 
therefore been difficult since obj ective param eters allowing de-
termination of the activity of the disease are lackin g. 
Co llagen is the m ain st ru ctura l glycoprotein of connective tis-
sue and exists in at least 10 different types [6]. Several collagen 
types are synthesized in a precursor form, called procoll agen , 
containin g add iti onal N- and C-terminal procollagen peptides, 
w hich are released en bloc durin g conversion into collagen by 
specific proteases [7] . A disturbed control of collagen synthesis 
has been found in fibroblasts derived fro m patients w ith PSS 
leading to an excessive overproduction of collagen types I and III 
[8-10]. 
Recently a radioimmunoassay for the amino propeptide o f type 
III proco ll agen has been used to m onitor conn ective tissue m e-
tabolism in liver diseases [11 - 15]. This antibody-based assay is 
sensitive enoug h to m easure aminopropeptide levels in norm al 
and patient sera and is considered to detect ac tive fibrotic processes 
in alcoholi c and chronic liver diseases [14] . It was also found th at 
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Most patients (89% ) with an active progression of the dis-
ease but not those in a stationary phase showed increased 
serum levels of aminopropeptides. Trea tment with corti-
cos teroids apparently normalized the levels of aminopro-
peptides. Only minor changes were observed with an an-
tibody-based radioimmunoassay which measures primarily 
the intact form of the aminopropeptide. J Invest D ermatol 
87: 788-791 , 1986 
this assay m easures primarily the intact (orm of aminopropeptide 
as it is o rginally released fro m procollagen III. T he assay fai ls due 
to a low affi nity to quantitate sufficiently som e degraded forms 
of the aminopropeptide which predominate in serum [11 ,16-18]. 
A more co mplete analysis of aminopropeptides in serum and urine 
recently beca m e avai lable with an assa y based on antibody Fab 
fragments whi ch does not distin guish betw een the various forms 
of the anti gen [18]. This assay also demonstrated elevated levels 
of serum amino pro peptide in liver patients but had not yet been 
applied to other clinical studies . H ere w e report on the use of this 
assay in patients w ith PSS and the co rrelation of serum peptide 
levels with the activity of the disease. 
MATERIALS AND METHODS 
Radioirnrnunoassays The radioimmunoassay with Fab fra g-
ments was carried out as described previously [18] . This radioim-
munoassay m easures both intact and degraded forms of the ami-
nopropeptide. The deg raded forms of the aminopropeptide have 
a m olecular m ass of abo ut 10,000 and correspond to the CoIl 
(Ill) portion of the peptide [11]. The values determined in the 
serum of 53 volunteers (age range, 20-65 years) was 40 ± 12 ng/ 
ml , indica ting a normal ran ge from 16-64 ng/ml [1 8]. A radioim-
munoassay kit usin g intact antibodies [11] instead of Fab fra g-
m ents was o btained fro m Behringwerke AG and kindly given to 
us by Dr. D. Brocks, H oechst AG . Serum was obtained from 
patients with PSS and controls and kept at - 20°C. 
Selection and Characterization of Patients Patients with 
PSS were differentiated according to the ARA criteria [1 9] in 4 
different centers in West Germany and their sera w ere collected . 
The patients were classifi ed according to the involvem ent o f skin: 
type I had invo lvement of the hands up to the wrist; in type II , 
fibrosis had started at the fin gers but also involved areas proximal 
to th e wrist; whereas in type Ill, fi brosis usually had started at 
the trunk [20]. For so m e studies patients with PSS type II were 
subgrouped into III (involvem ent of the arms) type 11 2 (involve-
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ment of arms and upper part of the trunk) , and type II} (involve-
men t of th e extremities and large areas of the trunk). Intern al 
m.a nifes tatio ns w ere exa mined by routine lung function tests and 
b y esophagea l scintigra phy . Severity of skin in volvement was 
es timated in all 'involved areas with a score of 1-6. The patients 
were followed durin g a period of 9 months. Progression of the 
disease was noted when an increase of skin invo lvement o r de-
teri oratio n of one of the interna l manifesta tions was fo und. Most 
of the patients (60%) remained without internal treatment, whereas 
others received o ral application of vasodilating drugs o r g luco-
corticosteroids. Liver function tests (GOT, G PT, 'Y-GT) were 
carried out in all patients included in this study. A ll patients had 
nornlal kidney functions as judged by creatinin in serum as well 
as crea tinin clearance. 
Statistical Analysis Statistica l ana lys is was ca rried o ut usin g 
Student's (-test. Values determin ed in sera of hea lth y volunteers 
were taken to define the no rm al range [11 , 181. 
RESULTS 
Sera of 101 patients with PSS diagnosed by established criteria 
[1 9 ] were included in this stud y. All pati ents had an intensive 
ph ysical examination before the blood samples were taken. Major 
cri t eria for judging development of the disease were invo lvement 
of the skin , alterati ons oflung function tests, and gas troesophageal 
clearance. ALI tes ts were repeated after a period of 9 m onths . 
From the investigated patients 31 were found to belo ng to PSS 
type I, 61 to type II , and 9 to type III. Sera of all th ese patients 
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Figure 1. Values of serum 3minopropeptidc of type III procollagen in 
101 patients with PSS as determined by 2 different radio immunoassays 
(antibody, Fab). T he dashed lilies denote upper limit of the normal ranges 
(mean ± 2 SO) determined to be 16 ng/ml for the antibody assay and 
64 n g/ml for the Fab assay [11 ,181· 
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Figure 2. Correla tion between serum 3minopropeptides determined by 
the Fab assay and extent of skin fibrosis in PSS patients. The mean ± 
SO for the different groups of patients are: I, 47 ± 14 (n = 27); II " 
52 ± 12 (n = 13); lb. 70 ± 27 (n = 23); Ib, 67 ± 12 (n = 16); III , 
88 ± 10 (n = 4). Valucs of groups 11 2, Ib, III were signifi cantl y higher 
(p < 0.005) co mpared with va lues observed in normal controls (40 ± 12 
ng/ ml). For the characteristi cs of each patient group (I to III ) see Ma terials 
alld Meth ods . T he dashed horizollial Ii" e indicates the upper limit of the 
norm al range. 
were analyzed for aminopropeptide levels by using both the an-
tibody- and Fab frag ment-based assays (Fig 1). Levels above the 
no rm al range were found in 41 % o f the patients by the Fab assay 
but in only 16% by the antibody assay. Half of the elevated values 
in the latter group were found in patients (n = 9) with impaired 
liver functions as judged fro m increased serum values of GOT, 
GPT, and ')I-GT . Since this indicates liver diseases which m ay 
increase amin opropeptide levels [11-14] all these patients were 
excluded from further comparisons . Serum levels of aminopro-
peptide as determined by the Fab-based assay in 83 patients with-
out liver involvement excluding also those on corticosteroid ther-
apy (see below) were compared for the extent of fibrotic lesions 
in skin (Fig 2). The data showed a good co rrelation between 
severity of disease and aminopropeptide levels : almost normal in 
patients of types f and n I (no trunk involvem ent) , elevated in 
50% of the patients with types Ih and II3 , and above the normal 
ran ge in all 4 patients of type III. There was also an obvious 
correlation between increased serum values and the involvement 
of m ore than one internal organ in fibrosis (Table f). 
Further studies were concerned with the prognostic value of 
the assay. Serum values of aminopropeptide were determined for 
83 patients at the beginning of the stud y w hi ch were then ex-
amined for progression of the disease by clinical criteria. Almost 
all patients with progression had abnorm ally high levels w hile 
Table I. Correlation Between the Involvem ent of Internal 
Organs in Progressive Systemic Scleroderma Patients and 
Serum Levels of Aminopropeptide 
O rgans Involved 
(pa tient number) 
None (18) 
Esophagus (22) 
Esophagus, lung (23) 
Esophagus, lung, 
heart (10) 
Mean Serum Level'; 
(ng/ml, ± SO) 
53 ± 15 
56 ± 20 
67 ± 24" 
71 ± 20b 
"Dctermincd by th c Fab assoy. 
Patients Above the 
Norm al Range ('Yo) 
22 
31 
48 
80 
'Significantly difrcrcnt fro m normal control group (p < 0.005). 
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Table II. Correlation Between Serum Levels of 
Am ino propeptide and C linical Progression o f the D isease 
Paticnts (n) 
Tota l (83) 
With progression (33) 
Without progression (50) 
"Determined by the Fa b assay. 
Mean Serum Level" 
(ng/ml , ± SO) 
60 ± 21b 
77 ± 20" 
49 ± 12 
Pat ients Above the 
Norm al Range 
(%) 
40 
89 
8 
'Signi fica ntl y d ifferen t fro m normal control group (p < U.005) . 
th ose w itho ut progression had, ill 111 0s t cases, va lues w ithin the 
norm al ra nge (Table II) . 
Another in vest igation was aimed at the possible influence o f 
therapeutic t rea tm en ts o n the se rul11 le vel o f amin o pro peptide. 
Patients w ho received trea tm en t w ith vasoact ive agents (n = 13) 
o r calcito nin (n = 18) were com pa rable to pa ti en ts witho ut trea t-
m en t (n = 53) w ith res pect to th eir serum values . All these 
patien ts belo nged to PSS types I and II and their data were used 
collecti vely in the correlation stud y (Fig 2; Ta bles I, II ) . Nine 
o ther pati ents belong in g to gro up 113 o r III were treated with 
corticostero ids (10-20 m g/day) and were all fo un d to have no rmal 
seru m levels. Fo ur other patients belo ng in g to group III were 
w itho ut t rea tm ent and had all serum levels above the no rm al 
range (Fig 2). 
D ISC U SSIO N 
P rogressive systemic scleroderm a is charac ter ized by an excessive 
accu m ulation of connective ti ss ue proteins in skin and o ther o r-
gans. T his correlates well with an in creased coll agen synth es is 
fo und in fi bro blas t cultures in abo ut 50% o f pati ents [8-10,21], 
w hich so fa r is the most rem arkable biochemica l defect o bserved 
in this disease. Some data also indi ca ted a co rrelati o n between 
enh an ced collagen synthesis and clini ca l ac ti vity of the disease [21] 
bu t the prognostic value of this co m pli cated analyt ica l approach 
rem ai ns q ues tionable . In creased levels of prolylh ydroxylase w ere 
also fo und in a limi ted number of skin bio psies fro m PSS pati ents 
[22] but no other laboratory tests are so fa r known fo r m o nito rin g 
fib rotic activ ity in this disease. 
H ere we repo rt o n in creased levels of circula tin g type III col-
lagen amino propeptide determined ill a large number o f patients 
by the Fa b radio immunoassay. T hi s assa y m easures both th e intact 
and degraded form s o f the amill o propeptide and shows a lo w 
intra- and interassay va riation [1 8]. E leva ted levels of amino pro-
peptide were found in 41 % of PSS patients with an average value 
in these patients of 82 ± 16 ng/ ml. T his average is 27% above 
the upper no rmal range (64 ng/ IIlI ). 
In creased aminopropeptide levels correl ated well w ith the ex-
tent of skin in volvem ent and number of inte rnal o rgans w ith 
fi brosis fo und in the patien ts. T his agrees w ith o ther o bserva tio ns 
onlJ1 creased prod ucti o n of both types I and III co ll agen in cultured 
scleroderm a fib ro blasts [8-10,21 J, indi catin g th at m easurem ent 
of either coll agen ty pe is useful fo r m o ni to rin g fibrosis. T he data 
also suggest that the serum levels of amin o pro peptide refl ect in -
creased coll agen biosynthesis and /o r connecti ve tiss ue remodelin g 
111 PSS patients. Sin ce the ca tabolism o f amin opropeptides in vivo 
IS lIl com pletely known [23] it is sti ll di fficult to d istin gui sh be-
tween the two possibilities. 
T he study also demo nstrated a co rrelat io n bet ween in creased 
seru m amino propeptide and cl inica l prog ressio n o f the disease. 
In contrast, histo logic analys is of skin biops ies ob ta ined fro l11 PSS 
patIents does no t necessaril y refl ect acti vity of the disease and 
cannot be often repea ted . T he course of disease is also no t entirely 
refle~ ted by immun ologic and infl ammato ry param ete rs [5]. Ex-
ceptions are cer ta in antinuclea r antibod y pattern s, w hich char-
actenze a su bgro up of PSS patients w ith a good prog nosis [24] . 
T he Jm inopropeptide assay seem s to have a broader p rognosti c 
po tential, but a precise correlatio n be tween all pattern s o f anti-
T I-IE JO UllNAL OF INV ESTIGATIVE DERM ATO LOGY 
nuclea r antibodi es in patien ts with PSS and the level of amin o-
pro peptides rem ains to be do ne. Because o f th e ubiquito us tissue 
distributi on of m os t connective tissue pro teins, assays fo r their' 
se rum fo rms m ay not be very specifi c fo r certain diseases; this 
m ay limi t their di agnos ti c bu t no t necessa rily their prognostic 
valu e. In creased serum levels o f amino pro peptide are commonly 
fo und in alcoho li c and so m e o ther fibro ti c li ver diseases by both 
the Fab assa y [1 81 and the antibod y-based assay [11-14] which 
llleasures m ainly the intact fo rm o f the peptide [11]. The latter 
assa y detected only small chan ges above th e no rm allevcl in so m e 
PSS patients and in about half o f them it might be due to an 
ongo in g liver fibr osis. Since impaired li ve r fun ctio n could be 
independent o f o r secondary to PSS the va lue of alllino pro peptide 
assays see m s to be questio nable in these patients. 
A further res tri ction of th e assay is o bvio us fo r all patients 
treated w ith co rticostero ids w ho had no rm al values o f amino-
propeptides in spite of ex tensive fibro ti c changes and rapid pro-
g ression o f the disease. Similar effects have been reported fo r 
circulatin g procollagen peptides in patients w ith Paget's disease 
11 5], and decrease of coll agen synth esis by g lu coco rticos tero ids 
has been o bserved in fibro blast cultures [25] . T ogether th e o b-
serva tio ns illdi cate th at th e in crease in serum amin op ropeptide in 
PSS patients is due to complex m etabo li c processes fo r whi ch w e 
still lack a mo lecular understandin g . T his must no t necessa ril y 
limit the prog nosti c value o f th e assay whi ch m ay also allow 
m onito rin g of treatment durin g active and in acti ve phases o f the 
disease . 
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